How is PCOS actually diagnosed?
Written and medically reviewed by Zahraa Sater, M.D., M.P.H.
Reviewed August 12, 2026 · Next review due August 12, 2028
Short answer
PCOS is diagnosed with the Rotterdam criteria: two of three features, which are irregular or absent ovulation, high androgens by symptoms or blood test, and polycystic ovarian morphology on ultrasound or a raised AMH. Look-alike conditions must be excluded first. In adults, if irregular cycles and high androgens are both present, no ultrasound is needed.
PCOS is diagnosed on a pattern, not on one test. The 2023 International Evidence-based Guideline keeps the Rotterdam criteria: two of three features are required, and conditions that mimic PCOS have to be excluded. The three features are ovulatory dysfunction, high androgens on examination or on blood testing, and polycystic ovarian morphology on ultrasound or a raised anti-Mullerian hormone level.
The three Rotterdam criteria
The Rotterdam criteria for PCOS are irregular or absent ovulation, hyperandrogenism, and polycystic ovarian morphology. Any two of the three make the diagnosis in an adult. The 2023 guideline adds a shortcut that changes practice: when a woman has both irregular cycles and hyperandrogenism, an ovarian ultrasound adds nothing and is not needed. Adolescents are held to a stricter standard. Both irregular cycles and hyperandrogenism are required, and neither ultrasound nor AMH is used, because normal puberty produces ovaries that look multifollicular.
What counts as an irregular cycle
The guideline defines irregular cycles by time since the first period. In the first year after menarche, irregular cycles are normal. From one to three years after menarche, cycles shorter than 21 days or longer than 45 days are irregular. From three years after menarche to perimenopause, the thresholds are cycles shorter than 21 days, longer than 35 days, or fewer than eight cycles in a year. After the first year, any single cycle longer than 90 days is abnormal.
Ultrasound thresholds and the AMH alternative
For polycystic ovarian morphology, the 2023 guideline sets the adult threshold at a follicle number per ovary of 20 or more in at least one ovary. Where image quality limits assessment, an ovarian volume of 10 mL or more, or 10 or more follicles per cross section, can be used instead. Serum AMH is now accepted as an alternative way of defining polycystic ovarian morphology in adults. The guideline is blunt about the limits: AMH "should not be used as a single test for the diagnosis of PCOS", and ultrasound and AMH should not both be done, to limit over-diagnosis.
| Method | Adult threshold | Guideline position |
|---|---|---|
| Transvaginal ultrasound | 20 or more follicles in at least one ovary | Preferred when acceptable to the patient |
| Older or transabdominal imaging | Ovarian volume 10 mL or more, or 10 or more follicles per section | Used when image quality is limited |
| Serum AMH | Population and assay specific cut-off set by the lab | An alternative to ultrasound, never a stand-alone diagnosis |
| Either test in adolescents | Not applicable | Not recommended |
What has to be excluded first
A short list of conditions produces the same picture as PCOS and has to be cleared. Thyroid function, prolactin, and an early morning 17-hydroxyprogesterone for nonclassic congenital adrenal hyperplasia are checked in most women. Pregnancy is excluded. Where symptoms came on quickly or include voice change or clitoral enlargement, Cushing syndrome and an androgen-producing tumour are considered.
Ask for named tests rather than "a hormone panel": total and free testosterone by mass spectrometry, early morning 17-hydroxyprogesterone in the follicular phase, prolactin, TSH, and a 75 g oral glucose tolerance test. One naming note: in May 2026 an international consensus renamed the condition polyendocrine metabolic ovarian syndrome, or PMOS, over a three year transition. The diagnostic criteria themselves did not change.
The clinical detail
2023 guideline specifics. Biochemical hyperandrogenism is assessed with total and free testosterone, with free testosterone estimated by calculated free androgen index (recommendation 1.2.1). Laboratories should use validated LC-MS/MS assays for total testosterone (1.2.3). Direct immunoassays for free testosterone are unreliable at female concentrations. Androgens cannot be interpreted on the combined oral contraceptive pill, which raises sex hormone binding globulin (1.2.6); allow at least three months off before testing.
Polycystic ovarian morphology in adults: follicle number per ovary 20 or more in at least one ovary using an 8 MHz or higher transducer. If AMH is used instead, laboratories should apply population and assay specific cut-offs (1.5.7). In those under 8 years post menarche who meet only part of the criteria, the guideline suggests labelling "increased risk" and reassessing at or before full reproductive maturity.
Written and medically reviewed by Zahraa Sater, M.D., M.P.H.
Reviewed August 12, 2026 · Next review due August 12, 2028
Sources
- International Evidence-based Guideline for the Assessment and Management of PCOS, 2023 summary. Monash University Centre for Health Research and Implementation
- Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism. PMID 37580314
- About Polycystic Ovary Syndrome (PCOS). NICHD, National Institutes of Health
- Polyendocrine Metabolic Ovarian Syndrome: new name for the condition previously called PCOS. Endocrine Society
This library is educational and is not individual medical advice. Read our Editorial and Medical Review Policy.